Simplex Trading
ABUS icon

Simplex Trading’s Arbutus Biopharma ABUS Stock Holding History

Simplex Trading’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,574
Closed -$68.4K – 9161
2026
Q1 		$70.1K Sell
15,574
-6,629
-30% -$29K ﹤0.01% 5494
2025
Q4 		$107K Sell
22,203
-18,760
-46% -$84.4K ﹤0.01% 4934
2025
Q3 		$185K Buy
40,963
+18,988
+86% +$69.7K ﹤0.01% 5027
2025
Q2 		$67K Sell
21,975
-14,154
-39% -$47K ﹤0.01% 5620
2025
Q1 		$126K Buy
36,129
+16,222
+81% +$54.1K ﹤0.01% 4816
2024
Q4 		$65K Sell
19,907
-45,387
-70% -$167K ﹤0.01% 5584
2024
Q3 		$251K Sell
65,294
-30,239
-32% -$116K ﹤0.01% 4298
2024
Q2 		$295K Buy
95,533
+7,403
+8% +$22.2K ﹤0.01% 4244
2024
Q1 		$227K Sell
88,130
-16,330
-16% -$42.3K ﹤0.01% 4704
2023
Q4 		$261K Buy
104,460
+79,069
+311% +$155K ﹤0.01% 4386
2023
Q3 		$51K Sell
25,391
-3,502
-12% -$7.34K ﹤0.01% 5775
2023
Q2 		$66K Buy
28,893
+23,963
+486% +$62.4K ﹤0.01% 5531
2023
Q1 		$14K Sell
4,930
-41,080
-89% -$116K ﹤0.01% 7227
2022
Q4 		$107K Buy
46,010
+5,454
+13% +$13K ﹤0.01% 4989
2022
Q3 		$77K Sell
40,556
-88,835
-69% -$209K ﹤0.01% 5867
2022
Q2 		$350K Sell
129,391
-423
-0.3% -$1.08K ﹤0.01% 3895
2022
Q1 		$386K Sell
129,814
-72,149
-36% -$221K ﹤0.01% 4201
2021
Q4 		$785K Buy
201,963
+171,920
+572% +$668K ﹤0.01% 3201
2021
Q3 		$94K Buy
30,043
+249
+0.8% +$830 ﹤0.01% 6700
2021
Q2 		$90K Buy
29,794
+13,839
+87% +$42.9K ﹤0.01% 6873
2021
Q1 		$0 Sell
15,955
-101,280
-86% -$391K ﹤0.01% 8633
2020
Q4 		$416K Buy
+117,235
New +$410K ﹤0.01% 3667
2020
Q1 		– Sell
-43,344
Closed -$117K – 7495
2019
Q4 		$120K Buy
43,344
+42,925
+10,245% +$69.5K ﹤0.01% 4315
2019
Q3 		$0 Sell
419
-252
-38% -$434 ﹤0.01% 7153
2019
Q2 		$1K Buy
+671
New +$1.72K ﹤0.01% 6836
2018
Q4 		– Sell
-7,700
Closed -$37.9K – 6890
2018
Q3 		$72K Sell
7,700
-1,851
-19% -$18.4K ﹤0.01% 4772
2018
Q2 		$69K Buy
9,551
+2,520
+36% +$15K ﹤0.01% 4706
2018
Q1 		$35K Buy
7,031
+4,238
+152% +$22.4K ﹤0.01% 2777
2017
Q4 		$14K Buy
+2,793
New +$16.4K ﹤0.01% 3614
2017
Q3 		– Sell
-1,914
Closed -$8.19K – 5785
2017
Q2 		$6K Buy
1,914
+1,005
+111% +$3.46K ﹤0.01% 4389
2017
Q1 		$2K Sell
909
-53,618
-98% -$149K ﹤0.01% 5187
2016
Q4 		$133K Buy
54,527
+33,389
+158% +$97.2K 0.01% 1317
2016
Q3 		$72K Buy
21,138
+14,028
+197% +$54.8K ﹤0.01% 1803
2016
Q2 		$24K Buy
7,110
+1,249
+21% +$5.29K ﹤0.01% 2723
2016
Q1 		$24K Buy
5,861
+3,226
+122% +$11.5K ﹤0.01% 2626
2015
Q4 		$11K Sell
2,635
-2,658
-50% -$14.6K ﹤0.01% 3186
2015
Q3 		$32K Sell
5,293
-7,451
-58% -$66.1K ﹤0.01% 2330
2015
Q2 		$151K Buy
12,744
+4,097
+47% +$62.3K 0.01% 949
2015
Q1 		$150K Buy
+8,647
New +$177K 0.02% 852

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Simplex Trading's ABUS Position: Q2 2026 in Review

Simplex Trading sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 15,574 shares — an estimated $68.4K sold.

Simplex Trading first reported a position in ABUS in Q1 2015 and held it in 39 quarters. The position peaked at $785K in Q4 2021. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Simplex Trading reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 15,574 Arbutus Biopharma shares in Q2 2026, an estimated $68.4K.
  • Simplex Trading first reported a position in Arbutus Biopharma in Q1 2015 and held it in 39 quarters.
  • Simplex Trading's Arbutus Biopharma position peaked at $785K in Q4 2021.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.